Browsing by Subject
Mostrando ítems 1-20 de 70
-
A pragmatic guide for management of adverse events associated with lorlatinib
(Elsevier, 2024-03-14) -
Brigatinib Versus Crizotinib in Advanced ALK Inhibitor–Naive ALK-Positive Non–Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial
(American Society of Clinical Oncology, 2020-11-01)